Regeneron Pharma (REGN) Reiterated at Overweight by Cantor Fitzgerald Ahead of Q1 Call
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $800.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
